| Objective:To investigate the correlation between tumor specimens STMN1,Bub R1,Bcl-2,Bad and the effect of chemotherapy with paclitaxel-containing regimen in patients with esophageal cancer.Methods:A total of 86 patients with esophageal squamous cell carcinoma who received paclitaxel-containing regimen chemotherapy in a grade-A hospital in Shanxi province from September 2016 to June 2021 were selected.The clinical data of the patients were retrospectively analyzed and followed up.The expression levels of STMN1,Bub R1,Bcl-2 and Bad in tumor tissues before chemotherapy were detected by immunohistochemical method,and the patients were divided into high expression group and low expression group according to the mean staining score of each protein.The imaging efficacy after 3 cycles of chemotherapy and pathological efficacy after neoadjuvant therapy were evaluated according to response evaluation criteria in Solid Tumors(RICIST)1.1 and tumor regression grade(TRG)score of the Society of American Pathologists(CAP).The relationship between clinicopathological factors and the expression of each protein was analyzed,and the differences in imaging efficacy and pathological efficacy progression-free survival between the high expression group and the low expression group of each protein were compared.Results:The proportion of low differentiation in patients with high expression of STMN1(22%,9/41)was higher than that in patients with low expression of STMN1(4.4%,2/45),and the rate of lymph node metastasis(95.1%,39/41)was higher than that in patients with low expression of STMN1(64.4%,29/45),the difference was statistically significant(P=0.047,P<0.001).There was no statistical difference in age and stage between patients with high and low expression of STMN1.Other patients with high or low expression of Bub R1,Bcl-2 and Bad had no statistical difference in age,stage and differentiation degree.In the imaging efficacy evaluation,the chemotherapy sensitivity rate of patients with high expression of STMN1(29.3%,12/41)was lower than that of patients with low expression of STMN1(75.6%,34/45),the difference was statistically significant(X~2=18.476,P<0.001).The chemotherapy sensitivity rate of patients with high Bub R1 expression(47.8%,22/58)was lower than that of patients with low Bub R1expression(85.7%,24/28),and the difference was statistically significant.(P<0.001).The chemotherapy sensitivity rate of patients with high Bad expression(65.9%,27/41)was higher than that of patients with low Bad expression(42.2%,19/45),and the difference was statistically significant(X~2=4.816,P=0.028).There was no significant difference in chemotherapy sensitivity rate of patients with high or low Bcl-2 expression.In the pathological efficacy evaluation,the proportion of patients with high expression of STMN1 whose TRG score was 0-1 after neoadjuvant chemotherapy(27.3%,3/11)was lower than that of patients with low expression of STMN1(75.6%,12/16),and the difference was statistically significant(P=0.022).There was no statistical significance in the proportion of patients with high or low expression of Bub R1,Bcl-2 and Bad after neoadjuvant chemotherapy.In the comparison of progression-free survival,PFS in patients with high expression of STMN1 were lower than those in the group with low expression of STMN1,the difference was statistically significant(X~2=12.902,P<0.001).PFS of patients with high Bub R1 expression were lower than those with low Bub R1expression,and the difference was statistically significant(X~2=12.038,P<0.001).PFS of patients with high Bad expression was higher than those with low Bad expression,and the difference was statistically significant(X~2=9.691,P=0.002).There was no significant difference in PFS between patients with high Bcl-2 expression and patients with low Bcl-2 expression(X~2=1.426,P=0.232).Conclusion:ESCC patients with low expression of STMN1,low expression of Bub R1 and high expression of Bad have better chemotherapy effect after receiving paclitaxel regimen.There is little correlation between Bcl-2 expression and chemotherapy efficacy. |
PDF Full Text Request